Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion

HIV Medicine

Volumn 8, Issue 4, 2007, Pages 213-219

  Laurichesse, Jacques J ^a,d   Persoz, A ^a   Theodorou, I ^b   Rouzioux, C ^c   Delfraissy, J F ^a   Meyer, L ^a  

^a BICÊTRE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; FRANCE; GENE DELETION; GENETIC CODE; HEMOPHILIA; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RNA ANALYSIS; SEROCONVERSION; TREATMENT DURATION; VIRUS DETECTION; VIRUS LOAD; WILD TYPE;

ADULT; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DNA; FEMALE; GENE DELETION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; POLYMERASE CHAIN REACTION; RECEPTORS, CCR5; RNA, VIRAL; VIRAL LOAD;

EID: 34247848047     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00455.x     Document Type: Article

References (36)

1. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
2. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
3. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
4. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCD5 delta Seroco Study Group. Lancet 1997; 349: 1219-1220.
5. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature Med 1997; 3: 252-253.
6. O'Brien TR, Winckler C, Dean M et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997; 349: 1219.
7. Meyer L, Mageirowska M, Hubert JB et al. Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS 1997;11: F73-F78.
8. de Roda Husman AM, Koot M, Cornelissen M et al. Association between CCR5 genotype and the clinical course of HIV-1 virus infection. Ann Intern Med 1997; 127: 882-890.
9. Meyer L, Magierowska M, Hubert JB et al. CCR5 Δ32 deletion and reduced risk of toxoplasmosis in HIV-1 infected patients. J Infec Dis 1999; 180: 920-924.
10. Ioannidis JP, Rosenberg PS, Goedert JJ et al. International Meta-Analysis of HIV Host Genetics. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135: 782-795.
11. Wu L, Paxton WA, Kassam N et al. CCR5 levels and expression pattern correlate with infectability to macrophage tropic HIV-1 in vitro. J Exp Med 1997; 185: 1681-1691.
12. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Eng J M 1997; 337: 725-733.
13. Gulick RM, Mellors JW Havlir et al. Treatment with Indinavir, Zidovudine and Lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Eng J Med 1997; 337: 734-739.
14. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997; 126: 939-945.
15. Carpenter CC, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997; 277: 1962-1969.
16. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-1686.
17. Mezzaroma I, Carlesimo M, Pinter E et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999; 29: 1423-1430.
18. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401-410.
19. Mocroft A, Devereux H, Kinloch-de-Loes S et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000; 4: 1545-1552.
20. Yamashita TE, Phair JP, Munoz A et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-746.
21. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251-2257.
22. Babiker A, Darbyshire J, Pezzotti P et al. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. J Acquir Immune Defic Syndr 2003; 32: 303-310.
23. Guerin S, Meyer L, Theodorou I et al. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000; 14: 2788-2790.
24. Valdez H, Purvis SF, Lederman MM, Filingame M, Zimmerman PA. Association of the CCR5 delta32 mutation with improved response to antiretroviral therapy. JAMA 1999; 8: 734.
25. Kasten S, Goldwich A, Schmitt M et al. Positive influence of the Δ32 CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patiens. Eur J Med Res 2000; 5: 323-328.
26. Bogner JR, Lutz B, Klein HG, Pollerer C, Troendle U, Goebel FD. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV medicine 2004; 5: 264-272.
27. O'Brien TR, McDermott DH, Ioannidis JP et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000; 14: 821-826.
28. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998; 12: 2193-2202.
29. Brumme ZL, Chan KJ, Dong W et al. CCR5 Δ32 and promoter polymorphism are not correlated with initial virological or immunological treatment response. AIDS 2001; 15: 2259-2266.
30. Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. CC chemokine receptor 5 Δ32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immuodeficiency virus type 1-infected patients. J Infec Dis 2002; 186: 1726-1732.
31. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
32. Reynes J, Portales P, Segondy M et al. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Inf Dis 2000; 181: 927-932.
33. Lathey JL, Tierney C, Chang SY et al. Association of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human Immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Inf Dis 2001; 184: 1402-1411.
34. Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Inf Dis 2005; 192: 466-474.
35. Hunt PW, Harrigan PR, Huang W et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Inf Dis 2006; 194: 926-930.
36. Agrawal L, Lu X, Qingwen J et al. Role for CCR5 Δ32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004; 78: 2277-2287.